148 related articles for article (PubMed ID: 19228938)
1. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N; Alchalby H; Klyuchnikov E; Badbaran A; Hildebrandt Y; Ayuk F; Bacher U; Bock O; Kvasnicka M; Fehse B; Zander A
Blood; 2009 Feb; 113(8):1866-8. PubMed ID: 19228938
[No Abstract] [Full Text] [Related]
2. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N; Badbaran A; Holler E; Hahn J; Kobbe G; Bornhäuser M; Reiter A; Zabelina T; Zander AR; Fehse B
Blood; 2007 Feb; 109(3):1316-21. PubMed ID: 17018857
[TBL] [Abstract][Full Text] [Related]
3. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
4. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O; Koren-Michowitz M; Amariglio N; Kroger N; Nagler A; Shimoni A
Leukemia; 2008 Oct; 22(10):1961-3. PubMed ID: 18685610
[No Abstract] [Full Text] [Related]
5. Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
Torka P; Hahn T; Bertolo J; Liu H; Ross M; Paplham P; Jankowski A; Deeb G; Chen G; McCarthy P
Bone Marrow Transplant; 2015 Nov; 50(11):1480-2. PubMed ID: 26214139
[No Abstract] [Full Text] [Related]
6. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
7. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
8. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.
Lee JM; Ahn A; Min EJ; Lee SE; Kim M; Kim Y
Blood Cancer J; 2023 Jun; 13(1):97. PubMed ID: 37365186
[No Abstract] [Full Text] [Related]
9. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
10. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.
Shah MV; Patel KP; Luthra R; Kanagal-Shamanna R; Mehrotra M; Bachegowda LS; Champlin RE; Verstovsek S; Popat UR
Br J Haematol; 2018 Dec; 183(5):831-835. PubMed ID: 29265180
[No Abstract] [Full Text] [Related]
11. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect.
Cervantes F; Rovira M; Urbano-Ispizua A; Rozman M; Carreras E; Montserrat E
Bone Marrow Transplant; 2000 Sep; 26(6):697-9. PubMed ID: 11035377
[TBL] [Abstract][Full Text] [Related]
12. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H; Badbaran A; Zabelina T; Kobbe G; Hahn J; Wolff D; Bornhäuser M; Thiede C; Baurmann H; Bethge W; Hildebrandt Y; Bacher U; Fehse B; Zander AR; Kröger N
Blood; 2010 Nov; 116(18):3572-81. PubMed ID: 20489052
[TBL] [Abstract][Full Text] [Related]
13. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
[TBL] [Abstract][Full Text] [Related]
14. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy.
Siebolts U; Lange T; Niederwieser D; Wickenhauser C
J Clin Pathol; 2010 Apr; 63(4):370-2. PubMed ID: 20354212
[TBL] [Abstract][Full Text] [Related]
16. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
[TBL] [Abstract][Full Text] [Related]
17. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect.
Byrne JL; Beshti H; Clark D; Ellis I; Haynes AP; Das-Gupta E; Russell NH
Br J Haematol; 2000 Feb; 108(2):430-3. PubMed ID: 10691877
[TBL] [Abstract][Full Text] [Related]
18. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
19. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
